首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1741493

皮肤癌治疗市场按药物类型、癌症类型、给药途径、分销管道和地区划分

Skin Cancer Drugs Market, By Drug Type, By Cancer Type, By Route of Administration, By Distribution Channel, By Geography

出版日期: 2025年03月27日 | 出版商:

Coherent Market Insights | 英文 150 Pages | 商品交期: 2-3个工作天内

价格

简介目录

皮肤癌药物市场规模预计在 2025 年达到 103 亿美元，预计到 2032 年将达到 180 亿美元，2025 年至 2032 年的复合年增长率为 8.3%。

报告范围		报告详细信息
基准年	2024	2025年的市场规模	103亿美元
效能数据	2020-2024	预测期	2025-2032
预测期：2025-2032年复合年增长率：	8.30%	2032年价值预测	180亿美元

皮肤癌是一种影响皮肤细胞的癌症，主要由暴露于太阳或日光浴床的紫外线 (UV) 辐射引起。它是全球最常见的癌症之一，且发生率逐年上升。为了应对这一成长趋势，製药公司正致力于开发和创新治疗皮肤癌的药物。

市场动态：

皮肤癌药物市场的成长主要源自于全球皮肤癌发生率的上升。过度暴露于紫外线、生活方式的改变以及人口老化等因素都导致了皮肤癌发病率的上升。此外，治疗性介入的进步和标靶治疗的引入也进一步推动了市场的成长。

然而，市场扩张仍面临许多挑战。高昂的药物开发成本和严格的监管要求是新参与企业面临的主要障碍。此外，某些药物的副作用以及替代治疗方案的可用性也限制市场的成长。

儘管面临诸多挑战，市场仍蕴藏着许多成长机会。研发投入的增加以及製药公司与研究机构之间合作的加强，预计将推动创新和新型治疗方案的推出。此外，个人化医疗和联合治疗的日益普及也为市场扩张提供了潜力。

本研究的主要特点

本报告对全球皮肤癌治疗市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模和年复合成长率（CAGR%）。
它还强调了各个领域的潜在商机，并说明了该市场的有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
它根据公司亮点、产品系列、关键亮点、财务表现和策略等参数，介绍了全球皮肤癌治疗药物市场的主要企业概况。
本报告的见解将使负责人和企业经营团队能够就未来的产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
全球皮肤癌药物市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
相关人员可以透过用于分析全球皮肤癌治疗药物市场的各种策略矩阵来更轻鬆地做出决策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 10.3 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	8.30%	2032 Value Projection:	USD 18.00 Bn

Skin cancer is a type of cancer that affects the skin cells and is primarily caused by exposure to ultraviolet (UV) radiation from the sun or tanning beds. It is one of the most prevalent cancers globally, and its incidence has been increasing over the years. To combat this rising trend, pharmaceutical companies have been focusing on the development and innovation of skin cancer drugs.

Market Dynamics:

The skin cancer drugs market is primarily driven by the rising incidence of skin cancer worldwide. Factors such as excessive exposure to UV radiation, changing lifestyles, and an aging population contribute to the increasing prevalence of the disease. Moreover, advancements in therapeutic interventions and the introduction of targeted therapies have further fueled market growth.

However, there are several challenges that hinder the market's expansion. High drug development costs and stringent regulatory requirements pose significant barriers for new entrants. Additionally, adverse side effects associated with certain drugs and the availability of alternative treatment options act as restraining factors for market growth.

Despite these challenges, the market presents several opportunities for growth. Increasing investments in research and development activities, along with collaborations between pharmaceutical companies and research institutions, are expected to drive innovation and the introduction of novel treatment options. Moreover, the growing focus on personalized medicine and the use of combination therapies offer potential avenues for market expansion.

Key features of the study:

This report provides in-depth analysis of the global skin cancer drugs market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global skin cancer drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novartis, Merck, Roche, Amgen, Pfizer, Sun Pharma, Bristol-Myers Squibb, AstraZeneca, Johnson & Johnson, Valeant, and others
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global skin cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global skin cancer drugs market

Detailed Segmentation:

By Type
- Melanoma Drugs
- Non-Melanoma Skin Cancer Drugs
- Actinic Keratosis Drugs
- Others
By Route of Administration
- Topical
- Oral
- Injectable
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
By Mechanism of Action
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Photodynamic Therapy
- Others
By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Company Profiles
- Novartis
- Merck
- Roche
- Amgen
- Pfizer
- Sun Pharma
- Bristol-Myers Squibb
- AstraZeneca
- Johnson & Johnson
- Valeant
- Daiichi Sankyo
- Takeda
- LEO Pharma
- Mylan
- Sanofi
- Regeneron
- Eli Lilly
- Bayer
- Gilead Sciences
- Astellas Pharma

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Cancer Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Increasing incidence of skin cancers
- High costs of targeted therapies
- Combination therapies
Key Highlights
Regulatory Scenario
Recent Trends
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Mergers, Acquisitions, and Collaborations

4. Global Skin Cancer Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Skin Cancer Drugs Market, By Drug Type, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Chemotherapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Targeted Therapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Immunotherapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Hormone Therapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Others (Photodynamic Therapy, Cryotherapy and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Skin Cancer Drugs Market, By Cancer Type, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Basal cell carcinoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Squamous cell carcinoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Melanoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Others (Kaposi's sarcoma, Mycosis fungoides and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Global Skin Cancer Drugs Market, By Route of Administration, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Others (Surgical procedures, radiation therapy and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

8. Global Skin Cancer Drugs Market, By Distribution Channel, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

9. Global Skin Cancer Drugs Market, By Region, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, By Sub-region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Sub-region, 2021 -2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Bn)
  - South Africa
  - North Africa
  - Central Africa

10. Competitive Landscape

Company Profile
- Novartis
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
- Merck
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Roche
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Amgen
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Pfizer
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Sun Pharma
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Bristol-Myers Squibb
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- AstraZeneca
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Johnson & Johnson
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Valeant
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Daiichi Sankyo
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Takeda Pharmaceutical
Company Limited
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- LEO Pharma
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Mylan N.V.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Sanofi
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Regeneron
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Eli Lilly
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Bayer
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Gilead Sciences
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Astellas Pharma
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Analyst Views

11. Section

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

皮肤癌治疗市场按药物类型、癌症类型、给药途径、分销管道和地区划分